Alexion acquires investigational therapy for MoCD Type A ultra-rare genetic disorder from Orphatec Alexion Pharmaceuticals, Inc. announced that it offers purchased patents and possessions from Germany-centered Orphatec Pharmaceuticals GmbH related to an investigational therapy for sufferers with molybdenum cofactor deficiency Type A, a devastating ultra-rare genetic disorder characterized by severe brain harm and rapid loss of life in newborns. Orphatec can be a kept development-stage biotechnology firm with headquarters in Cologne privately, Germany. In addition, Alexion has established a research collaboration with crucial MoCD researchers from Orphatec to accelerate development of the investigational therapy.?.Repeat contact with stomach acids can lead to harm to the esophagus and cause healthy cells to transform into these precancerous cells. Regrettably, many individuals with Barrett’s Esophagus could be asymptomatic. Related StoriesFDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLCMeat-rich diet may increase kidney malignancy riskMD Anderson research reveals why chemotherapy medicines not effective for most pancreatic cancer sufferers The incidence of esophageal cancer tumor is increasing more rapidly than any other type of cancer in the United States and survival rates remain low, said Northwestern Medication gastroenterologist Srinadh Komanduri, MD.